Current status of immunomodulatory therapies in adult sepsis patients: where do we stand? - PubMed
3 hours ago
- #immunomodulation
- #sepsis
- #precision medicine
- Sepsis remains a leading cause of morbidity and mortality despite advances.
- Dysregulated host responses characterize sepsis, leading to numerous failed immunomodulatory clinical trials.
- Heterogeneity of host immune responses is a key reason for the failure of past therapies.
- Personalized precision immunotherapy approaches, guided by biomarkers, now show promise.
- Recent studies have identified biomarkers that classify patients into distinct endotypes and predict treatment response.
- Biomarkers can aid in patient selection, timing of treatment, and adaptation to different endotypes.
- Integration of immune monitoring, adaptive trial designs, and endotype-specific algorithms could advance sepsis treatment.